News

Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2. Themis has a pipeline of vaccine candidates and immune modulatory therapies developed using its...

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in...

Glenmark Pharmaceuticals announced on Tuesday that it will commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India. Glenmark has received approval from the...

AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC). ArcherDX’s personalised assay will be used in...

SIRIO Europe (Ayanda) – the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO) – says considerable worldwide demand for immunity products has accelerated in recent months due coronavirus, but it is...

US pharmaceutical giant Gilead Sciences is likely to apply to India's Central Drugs Standard Control Organisation (CDSCO) soon seeking marketing authorisation for its anti-viral drug remdesivir, which is being considered by many as a potential medication for COVID-19. Officials of...

Pfizer has reported new data from the Phase Ib clinical trial of PF-06939926 for the treatment of patients with Duchenne muscular dystrophy (DMD). PF-06939926 is an experimental, recombinant adeno-associated virus serotype 9 (AAV9) capsid with a shortened variant of the...